Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 25, 2026, 10:39 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–16 of 16 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Warm Autoimmune Hemolytic Anemia (WAIHA) Clear all
Completed Phase 2 Interventional

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT04691570
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
ANX005
Drug
Lead sponsor
Annexon, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 18, 2024 · Synced Jun 25, 2026, 10:39 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA

NCT03764618
View directory record Official record
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Fostamatinib disodium, Placebo
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
26
States / cities
Gilbert, Arizona • Phoenix, Arizona • Tucson, Arizona + 22 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Jun 25, 2026, 10:39 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia

NCT05648968
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
Ianalumab, Placebo
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
3
States / cities
Farmington Hills, Michigan • Minneapolis, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Jun 25, 2026, 10:39 PM EDT
Completed Phase 2 Interventional Results available

Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemolytic Anemia (wAIHA) or Cold Agglutinin Disease (CAD)

NCT03226678
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Interventions
APL-2
Drug
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Whittier, California • Miami Lakes, Florida • Orange City, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jun 25, 2026, 10:39 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Pharmacokinetics, and Efficacy of Subcutaneous Isatuximab in Adults With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT04661033
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
Isatuximab SAR650984
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Jun 25, 2026, 10:39 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia

NCT04119050
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
M281, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
29
States / cities
Fountain Valley, California • Los Angeles, California • Riverside, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 25, 2026, 10:39 PM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia

NCT07086976
View directory record Official record
Conditions
Autoimmune Haemolytic Anaemia
Interventions
rilzabrutinib, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jun 25, 2026, 10:39 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias

NCT05757570
View directory record Official record
Conditions
Immune Thrombocytopenia, Idiopathic Thrombocytopenic Purpura, Warm Autoimmune Hemolytic Anemia, Cold Agglutinin Disease
Interventions
povetacicept
Drug
Lead sponsor
Alpine Immune Sciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
15
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Cooper City, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2025 · Synced Jun 25, 2026, 10:39 PM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia

NCT04138927
View directory record Official record
Conditions
Warm Antibody Autoimmune Hemolytic Anemia
Interventions
Fostamatinib disodium
Drug
Lead sponsor
Rigel Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Los Angeles, California • Torrance, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Jun 25, 2026, 10:39 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy, Safety and Pharmacokinetics of Rilzabrutinib in Patients With Warm Autoimmune Hemolytic Anemia (wAIHA)

NCT05002777
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
rilzabrutinib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
11
States / cities
Cerritos, California • Glendale, California • Long Beach, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Jun 25, 2026, 10:39 PM EDT
Terminated Phase 3 Interventional Results available

Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia

NCT05073458
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (wAIHA)
Interventions
parsaclisinib, placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
10
States / cities
Los Angeles, California • Whittier, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jun 25, 2026, 10:39 PM EDT
Terminated Phase 2 Interventional Results available

To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).

NCT04253236
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
RVT-1401 680 mg/weekly, RVT-1401 340 mg/weekly
Drug
Lead sponsor
Immunovant Sciences GmbH
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Iowa City, Iowa • Louisville, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2022 · Synced Jun 25, 2026, 10:39 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease

NCT07549698
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia (WAIHA), ITP - Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia, Immune Thrombocytopenic Purpura
Interventions
CTX112
Biological
Lead sponsor
CRISPR Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
2
States / cities
Rochester, Minnesota • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Jun 25, 2026, 10:39 PM EDT
Withdrawn Phase 2 Interventional

Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia

NCT04956276
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
ALXN1830, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Riverside, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Jun 25, 2026, 10:39 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA)

NCT03075878
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
ALXN1830
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jun 25, 2026, 10:39 PM EDT
Withdrawn Phase 2 Interventional

ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia

NCT04256148
View directory record Official record
Conditions
Warm Autoimmune Hemolytic Anemia
Interventions
ALXN1830, Placebo
Biological · Other
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Whittier, California
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Jun 25, 2026, 10:39 PM EDT